Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Splenectomized thalassemia major subjects were provided with PCV pneumococcal vaccine (Prevenar 13®) at the start of the trial, following which they were randomly assigned to 2 groups (zinc and placebo group). After 8 weeks, the subjects received PPV pneumococcal vaccine (Pneumovax®). Zinc syrup was provided to the zinc group at a dose of 1.5 mg/kg/day (maximum of 50 mg/day). Pneumococcal IgG examinations were conducted at the start of the trial and after 12 weeks.
Epistemonikos ID: f59d7879f7b6a505111d94331726b58d0ad72b9c
First added on: May 20, 2024